Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin.
Daptomycin, a new cyclic lipopeptide, was recently approved for the treatment of infections by gram-positive organisms, including infections with methicillin-resistant Staphylococcus aureus (MRSA). A patient infected with infected with MRSA developed resistance to daptomycin after prolonged exposure, which resulted in clinical failure. Clinicians should be aware of the possibility of daptomycin resistance and should consider routine testing for daptomycin susceptibility.
Skiest
Daniel J
DJ
Baystate Medical Center, Division of Infectious Diseases, 759 Chestnut St., Springfield, MA 01199, USA. daniel.skiest@bhs.org
D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D017576:Daptomycin / Q000494:pharmacology* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects*; D017211:Treatment Failure
D000900:Anti-Bacterial Agents; D017576:Daptomycin